Signal detection to identify serious adverse events (neuropsychiatric events) in travelers taking mefloquine for chemoprophylaxis of malaria
Open Access
- 1 August 2012
- journal article
- Published by Taylor & Francis Ltd in Drug, Healthcare and Patient Safety
- Vol. 4, 87-92
- https://doi.org/10.2147/DHPS.S34493
Abstract
Background: For all medications, there is a trade-off between benefits and potential for harm. It is important for patient safety to detect drug-event combinations and analyze by appropriate statistical methods. Mefloquine is used as chemoprophylaxis for travelers going to regions with known chloroquine-resistant Plasmodium falciparum malaria. As such, there is a concern about serious adverse events associated with mefloquine chemoprophylaxis. The objective of the present study was to assess whether any signal would be detected for the serious adverse events of mefloquine, based on data in clinicoepidemiological studies. Materials and methods: We extracted data on adverse events related to mefloquine chemoprophylaxis from the two published datasets. Disproportionality reporting of adverse events such as neuropsychiatric events and other adverse events was presented in the 2 × 2 contingency table. Reporting odds ratio and corresponding 95% confidence interval [CI] data-mining algorithm was applied for the signal detection. The safety signals are considered significant when the ROR estimates and the lower limits of the corresponding 95% CI are ≥2. Results: Two datasets addressing adverse events of mefloquine chemoprophylaxis (one from a published article and one from a Cochrane systematic review) were included for analyses. Reporting odds ratio 1.58, 95% CI: 1.49–1.68 based on published data in the selected article, and 1.195, 95% CI: 0.94–1.44 based on data in the selected Cochrane review. Overall, in both datasets, the reporting odds ratio values of lower 95% CI were less than 2. Conclusion: Based on available data, findings suggested that signals for serious adverse events pertinent to neuropsychiatric event were not detected for mefloquine. Further studies are needed to substantiate this.Keywords
This publication has 28 references indexed in Scilit:
- Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reportingJournal of Asthma and Allergy, 2012
- Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug MonitoringMalaria Journal, 2011
- The position of mefloquine as a 21st century malaria chemoprophylaxisMalaria Journal, 2010
- Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxisEuropean Journal of Clinical Pharmacology, 1997
- Mefloquine Compared with Doxycycline for the Prophylaxis of Malaria in Indonesian SoldiersAnnals of Internal Medicine, 1997
- Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellersBMJ, 1996
- Severe Psychiatric Side Effects Observed During Prophylaxis and Treatment With MefloquineArchives of Internal Medicine, 1994
- Mefloquine Prophylaxis Prevents Malaria during Pregnancy: A Double-Blind, Placebo-Controlled StudyThe Journal of Infectious Diseases, 1994
- A Comparative Study of Gastrointestinal Infections in United States Soldiers Receiving Doxycycline or Mefloquine for Malaria ProphylaxisThe American Journal of Tropical Medicine and Hygiene, 1990